Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 5/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7796077 | 1.00 | AKR1C3 (0.42) | AKR1C3SIRT2CYP11B1CYP11B2APEX1 | |
| SCHEMBL7621404 | 0.82 | CYP11B1 (0.40) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL6714982 | 0.78 | RAB9A (0.42) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL6714980 | 0.78 | RAB9A (0.42) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL2741592 | 0.78 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL223714 | 0.78 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL223715 | 0.78 | CYP11B1 (0.36) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL312750 | 0.77 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL8687555 | 0.76 | CYP11B1 (0.42) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL6926961 | 0.76 | KDM4E (0.43) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047100-A1 | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives | KJAERSGAARD HANS JOERGEN (DK) | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047100-A1 | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives | HRH4, HRH2, HRH1 | AKR1C3 2151/4885SIRT2 2591/4885CYP11B1 3958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.